NCT07331155 2026-03-09
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
Nanjing Leads Biolabs Co.,Ltd
Mirati Therapeutics Inc.
Tianjin Medical University Cancer Institute and Hospital
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)